Net Income - Protagonist Therapeutics Inc (NASDAQ:PTGX) - Alpha Spread

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 45.92 USD 2.57% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
Protagonist Therapeutics Inc?
Write Note

Protagonist Therapeutics Inc
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Protagonist Therapeutics Inc
Net Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
Protagonist Therapeutics Inc
NASDAQ:PTGX
Net Income
$170m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income
$5.4B
CAGR 3-Years
-7%
CAGR 5-Years
5%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income
-$384m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Income
$3.1B
CAGR 3-Years
-18%
CAGR 5-Years
-17%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income
-$489.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
4%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income
$4.3B
CAGR 3-Years
-11%
CAGR 5-Years
16%
CAGR 10-Years
27%

See Also

What is Protagonist Therapeutics Inc's Net Income?
Net Income
170m USD

Based on the financial report for Jun 30, 2024, Protagonist Therapeutics Inc's Net Income amounts to 170m USD.

Back to Top